Why Eyes Get Drier After Menopause: What the Research Shows

How common is dry eye after menopause, really?

Dry eye is not a minor cosmetic complaint. It is one of the most frequent reasons women visit an ophthalmologist in midlife, and the numbers back that up.

A 2023 cross-sectional study of 400 postmenopausal women at a tertiary care hospital, using the Schirmer's test to measure actual tear production, found dry eye in 39.75 percent of participants. Severity climbed with age, and the association was statistically significant.

That is not a fluke of one hospital. It fits a broader pattern researchers have documented for years:

• Dry eye disease occurs more frequently in women than men across every age group studied
• The gap widens sharply after menopause rather than staying flat
• Women report more severe symptoms for the same objective clinical findings than men do, a pattern the TFOS DEWS II Sex, Gender, and Hormones Report documented directly
• The condition is chronic for most women who develop it, not a passing phase

Why this gets missed

Dry eye rarely gets raised at a menopause visit the way hot flashes or sleep do, so many women assume the grittiness, the burning by evening, or the sudden sensitivity to wind and screens is just fatigue or allergies. The research says otherwise.

What is actually happening in the eye when estrogen drops?

The eye's surface depends on a thin, layered tear film to stay comfortable and clear. Hormone receptors sit directly on the tissue that builds it.

Researchers have documented estrogen, androgen, and progesterone receptor activity in the lacrimal gland (which produces the watery layer of tears), the meibomian glands (which produce the oily layer that keeps that water from evaporating), the cornea, and the conjunctiva. This is not a distant, indirect effect. The hormone-sensitive tissue is the tear-producing tissue.

The layer that gets overlooked

Most people picture dry eye as simply "not enough tears." The oily layer matters just as much.

1. The meibomian glands secrete lipids that form a thin oil film over the tear layer
2. That oil film is what slows evaporation, without it, tears can be produced normally and still evaporate too fast
3. Sex hormone receptors on the meibomian glands directly influence how much lipid gets secreted
4. When that regulation shifts at menopause, evaporation, not underproduction, is often the bigger problem

The honest complication here is that the direction of the effect is not simple. One study measuring tear samples from postmenopausal women found that higher estradiol levels were associated with more MMP-2 and MMP-9, enzymes that break down proteins in the tear film's protective structure. That does not mean estrogen is simply "bad" for the eye either; it means the hormonal picture is genuinely more layered than a single before-and-after story.

Does hormone therapy fix it?

If declining estrogen is part of the problem, restoring it sounds like the obvious answer. The clinical trial evidence is more complicated than that, and it is worth stating honestly rather than glossing over.

A phase II, multicenter, randomized, placebo-controlled trial tested a topical estradiol eye drop formulation against a vehicle (an inactive drop with no hormone) in postmenopausal women with moderate to severe dry eye disease. Both groups improved. The trial did not demonstrate a significant difference between the estradiol drops and the inactive vehicle on the primary Schirmer's test measure, though symptom improvement did appear somewhat earlier in the treated group. A separate meta-analysis of hormone replacement therapy trials found HRT improved Schirmer's test results but not tear break-up time or comfort scores.

Why a "simple fix" keeps not being simple

Hormone receptors being present in a tissue does not automatically mean adding the hormone back reverses everything that changed. The tear film is a multi-layer system, and putting one signal back does not guarantee every downstream piece recalibrates the same way. That is a pattern that shows up across several menopause-related tissue changes, not just the eye.

What does shilajit's own research show?

Shilajit is a mineral-rich resin, high in fulvic acid, that forms over centuries in the Altai mountains and has been studied in several human trials for entirely different endpoints. No trial has ever tested shilajit against a dry eye outcome, and none should be implied here.

What does exist is Optimum's own flagship human trial, led by Pingali and colleagues, which measured hsCRP and MDA, two markers of systemic inflammation and oxidative stress, and found meaningful reductions after shilajit supplementation. Fulvic acid, the active compound, has separately been shown in human monocyte studies to reduce inflammatory signaling through the same NF-kB pathway involved in many chronic irritation states. Shilajit's role in this article is the same general claim Optimum makes everywhere else. It supports the body's own estrogen signaling and lowers markers of inflammation and oxidative stress. That is not a claim that it treats or reverses dry eye specifically.

The gap between those two things matters.

• The inflammation and oxidative-stress mechanism is real and human-trial-confirmed, in a general sense
• The estrogen-signaling-support mechanism is the same one behind Optimum's bone, vascular, and skin research
• The bridge from "supports estrogen signaling generally" to "helps with dry eye specifically" has not been tested and this article does not claim it has
• Anyone considering shilajit for dry eye should understand that gap plainly before deciding anything

Is shilajit safe to try alongside eye drops?

Persistent dry eye, redness, or any change in vision deserves an actual eye exam before anything else. A Schirmer's test or a slit-lamp exam can rule out more serious causes in a few minutes.

Across every human clinical study conducted on shilajit, zero serious adverse events have been reported. Purity still matters more than almost anything else with this ingredient.

Not every product on the shelf is made the same way.

What to look for in a shilajit product

• Purified resin, not raw powder, since powder loses much of its fulvic acid during processing
• A verified fulvic acid percentage. Optimum tests every batch at 78 percent fulvic acid
• Third-party testing for heavy metals, since contaminated source material can carry lead and arsenic
• A clear country of origin. Optimum sources its resin from the Altai mountains, cold pressed with zero heat processing

Optimum is a small, family owned company out of Florida. This article describes what the published research measured; it is educational, not a substitute for an eye doctor's evaluation of your specific symptoms.

Optimum Shilajit

If you want the fulvic acid and trace minerals behind the estrogen-signaling and inflammation research above, sourced from the Altai mountains and tested for heavy metals on every batch, here is .

See Optimum Shilajit